Chugai Pharmaceutical Co., Ltd. (CHGCF)

26.46 0.00 (0.00%) At close: 09:30AM EST

Chugai Pharmaceutical Co., Ltd.

Nihonbashi Mitsui Tower
15th Floor 1-1 Nihonbashi-Muromachi 2-chome Chuo-ku
Tokyo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full-time employees: 7,664

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Osamu Okuda	Pres, CEO & Representative Director	449.9k	N/A	1963
Mr. Toshiaki Itagaki	Head of Fin. Supervisory Division, CFO, Exec. VP & Director	N/A	N/A	1960
Toshiya Sasai	Exec. of Investor Relations Group & Corp. Communications Department	N/A	N/A	N/A
Masahiko Uchida	Gen. Mang. of Corp. Communications Department	N/A	N/A	N/A
Mr. Shinji Hidaka	Exec. VP and Head of Marketing & Sales Division	N/A	N/A	N/A
Mr. Tsunanori Sato	VP and GM of Marketing & Sales Division	N/A	N/A	N/A
Mr. Yoshiyuki Yano	Exec. VP & Head of HR Management Department	N/A	N/A	N/A
Mr. Junichi Ebihara	Exec. VP	N/A	N/A	N/A
Dr. Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	N/A	N/A	1960
Mr. Tetsuya Yamaguchi	Exec. VP and Head of Project & Lifecycle Management Unit	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Corporate governance

Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 1 October 2022 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder rights: 8; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.